Dr. Kevin Pojasek is a Venture Partner at SV Health Investors and President and CEO of Ervaxx, an SV portfolio company.
He joined the SV Venture Partner Program in September 2018.
Prior to joining SV, Kevin was Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore Ltd. In this role, he was responsible for shaping the company’s corporate, R&D and growth strategies, as well as for overseeing business development. Kevin was also co-head of the company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40 million. Prior to joining Immunocore, Kevin was President, Chief Executive Officer of Quartet Medicine, a company he co-founded in late 2013 while working as an Entrepreneur-in-Residence at Atlas Venture.
Kevin was also the Chief Operating Officer of Annovation Biopharma, another Atlas Venture-funded company, which was sold to the Medicines Company in January 2015. He has also held senior executive R&D and corporate development roles at several venture capital-backed companies, including Vice President of Corporate Development at Kala Pharmaceuticals (NASDAQ:KALA) and, earlier in his career, spent time as an investment associate at PureTech Health (LSE: PRTC) an early stage venture capital firm.
PhD from the Biological Engineering Department at Massachusetts Institute of Technology; BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.